医学
心房颤动
内科学
盐皮质激素受体
心脏病学
糖尿病
肾脏疾病
纤颤
心房扑动
内分泌学
醛固酮
标识
DOI:10.1038/s41569-021-00571-y
摘要
Mineralocorticoid-receptor antagonism with the novel drug finerenone reduces the risk of new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes mellitus, according to a secondary analysis of the FIDELIO-DKD trial.
科研通智能强力驱动
Strongly Powered by AbleSci AI